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Abstract 
Nonmelanoma skin cancer is extremely common and is increasing in inci-
dence. It would be very useful to have forms of therapy that would prevent 
precancerous changes from going on to form cancer, or to reverse the precan-
cerous changes. Epidemiologic evidence in humans, in vitro studies on human 
cells, and clinical experiments in animals have identified polyphenol com-
pounds found in tea to be possibly useful in reducing the incidence of various 
cancers, including skin cancer. To examine the potential for a polyphenol 
from green tea, epigallocatechin gallate, to act as a chemopreventive agent for 
nonmelanoma skin cancer, a randomized, double-blind, placebo-controlled 
phase II clinical trial of topical epigallocatechin gallate in the prevention of 
nonmelanoma skin cancer was performed. 
Background 
Nonmelanoma skin cancer is a significant and increasing medical problem. In 
the United States, over one million new cases of nonmelanoma skin cancer are 
diagnosed each year, probably exceeding the incidence of all other types of 
cancer combined (Jemal et al. 2002). The two most common types of non-
melanoma skin cancer are basal cell carcinoma and squamous cell carcinoma. 
The greatest risk factors for these types of cancers are a fair skin type and 
high cumulative exposure to sunlight. 
The most readily identifiable premalignant lesion for nonmelanoma skin 
cancers is actinic keratosis (solar keratosis), which is considered to be a pre-
malignant precursor to squamous cell carcinoma. There is some controversy 
over this designation among dermatologists, some of whom consider actinic 
keratoses to be a form of squamous cell carcinoma in situ of the skin (Heaphy 
and Ackerman 2000). The risk factors for actinic keratoses are the same as 
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those for nonmelanoma skin cancer, as described above. Given these risk fac-
tors, it is not surprising that fair-skinned populations inhabiting sunny cli-
mates at latitudes closer to the equator such as Australia have the highest risk 
for, and incidence of, actinic keratoses (Marks 1990). 
Actinic keratoses are readily identifiable precursors to nonmelanoma skin 
cancer; as a result they are useful clinical markers for cancer prevention re-
search. Interventions that lead to the regression or decrease in the rate of for-
mation of actinic keratoses would be expected to lead to a decrease in the for-
mation of nonmelanoma skin cancers, particularly squamous cell carcinoma 
of the skin. It is for this reason that actinic keratoses are being extensively 
studied as modulable clinical endpoints in trials testing the chemopreventive 
potential of promising agents against the development of nonmelanoma skin 
cancer. 
The purpose of this chapter is to discuss important aspects of study design 
for clinical trials of potential chemopreventive agents administered to prevent, 
regress, or retard the development of actinic keratoses and nonmelanoma skin 
cancer. Our experiences with a polyphenol from green tea will be used as an 
example. 
Choice of Potential Chemopreventive Agents for Actinic Keratoses 
and Nonmelanoma Skin Cancer 
In choosing a candidate chemopreventive agent for nonmelanoma skin can-
cer, several factors must be considered. The factors include epidemiologic evi-
dence indicating that the chemopreventive agent may be useful in the preven-
tion of the cancer of interest and observational data on drugs developed for 
other applications (e.g., oncologic agents such as topical 5-fluorouracil). Ac-
tivity of the potential chemopreventive agent in animal model systems is an 
important form of preliminary evidence. Additionally, in vitro activity against 
precancerous and cancerous cells may be of use. If there is a potential molecu-
lar mode of action postulated for the agent, various forms of biochemical and 
molecular studies may be used to evaluate a potential chemopreventive agent 
as well. In our study of the chemoprevention of actinic keratoses and squa-
mous cell carcinoma, epigallocatechin gallate satisfied many of the above-
mentioned criteria for advancement into clinical testing. 
Epidemiologic evidence suggests that green tea may have anticancer activi-
ty against a number of cancers. However, the evidence is equivocal and vari-
ous studies in different populations show that green tea may be associated 
with a preventive effect, no effect, or even an increased risk of cancer in nearly 
every epithelial cancer studied (see Bushman 1998 for review). In addition to 
differences in study design, plant variety, growth conditions, horticultural 
practices, processing, and variable tea consumption may contribute to the 
mixed data arising from epidemiologic studies (Katiyar and Mukhtar 1997). 
The bulk of the epidemiologic evidence probably does favor some chemopre-
ventive effects for certain cancers. Animal model studies of epigallocatechin 
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gallate, a tea constituent, have demonstrated inhibitory effects against carci-
nogenesis at a number of organ sites. Particularly convincing preliminary evi-
dence is that the compound has been shown to reverse squamous papilloma 
formation in the mouse model of UV carcinogenesis that is most analogous to 
actinic keratoses in humans (Mukhtar et al. 1994; Gensler et al. 1996). There is 
also in vitro evidence using human skin cancer lines that epigallocatechin gal-
late may possess anticancer properties (Valeic et al. 1996). Numerous molecu-
lar mechanisms have been suggested to account for the possible chemopre-
ventive activity of green tea against various cancers. The polyphenols, includ-
ing epigallocatechin gallate, are powerful antioxidants that may act to quench 
free radicals produced during the carcinogenic process; also, they may act at 
many sites in the carcinogenic pathway (Dreosti 1997). Given the epidemio-
logic, animal model, in vitro, and molecular evidence, it was felt that epigallo-
catechin gallate was a good candidate agent for chemoprevention of human 
nonmelanoma skin cancer and a clinical trial was designed to test this hypoth-
esis. 
Another consideration is that any new chemopreventive agent will be 
judged against current therapies, which for actinic keratoses mainly consist of 
liquid nitrogen treatment, treatment with the topical chemopreventive agent 
5-fluorouracil, photodynamic therapy (Jeffes et al. 2001), and more recently, 
treatment with the topical agent diclofenac (Rivers et al. 2002). 
Clinical Trial Design for Chemoprevention of Nonmelanoma Skin Cancer 
There are several important elements that must be included in a clinical trial 
of potential chemopreventive agents for actinic keratoses and nonmelanoma 
skin cancer. The trial must include a control arm. This is essential because ac-
tinic keratoses and visual signs of photo damage are usually graded and moni-
tored clinically, which introduces a large element of subjectivity. For example, 
the application of emollient type vehicles can appear to regress actinic ker-
atoses and photo damage simply by inducing immediate surface changes. For 
these reasons, it is necessary that the study be double-blinded, such that nei-
ther study participants nor investigators know whether the area under evalua-
tion is being treated with the study agent or the placebo. Even for oral agents, 
the inherent subjectivity of clinical grading systems mandates inclusion of a 
control group and randomized, blinded studies. 
Study Population Considerations 
In regards to the population at risk and to be studied, the study cohort will 
primarily consist of fairer skinned individuals with a considerable amount of 
sun exposure. This translates into the need to recruit subjects mainly in their 
60s or older, though rarely people even as young as those in their late 20s may 
have enough sun damage and actinic keratoses to qualify as study subjects. 
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Study subjects can be referred from associated dermatology clinics or recruit-
ed directly from the community through directed advertising. For our study 
of a topical green tea polyphenol, study participants were recruited from asso-
ciated university and private dermatology clinics, and by various forms of 
print and radio advertising, which targeted the age demographics of the eligi-
ble study participants. 
Design of Treatment Methodologies in Skin Cancer 
Chemoprevention Studies 
Treatment methodology will depend on whether the agent is topical or oral. 
For topical formulations, study subjects can often serve as their own controls, 
with one body part designated as a target area to be treated with the active 
agent and the mirror area on the opposite side of the body receiving the place-
bo control. Again, the sides to receive the treatment and the control should be 
assigned in a random and double-blinded fashion. For clinical trials with oral 
agents, each participant must be randomized to active treatment or control, 
though there does not need to be an equal number of treatment and control 
subjects - the control arm can consist of a smaller number of study subjects. 
Statistical analysis will determine the proportion of subjects that should be al-
lotted to the control group so that the study achieves an acceptable balance 
between statistical power and the desire of subjects to receive potentially ac-
tive treatment rather than placebo. 
For our trial, epigallocatechin gallate was compounded in a topical vehicle 
to a final assayed concentration of 5.5-8.5%, 0.5 ml was applied by the subject 
nightly for l2 weeks to target actinic keratoses on one of the forearms. A 
matched placebo ointment was applied to target actinic keratoses on the op-
posite forearm. Prior to treatment, at least two actinic keratoses were identi-
fied on each forearm target area, and these target actinic keratoses were 
mapped, followed, and clinically graded at 2-week intervals during the 12-
week treatment period. 
Statistical Considerations in Treatment Methodology Design 
It is necessary to design the study such that it will have adequate power to de-
tect the hypothesized differences between the agent and the control group for 
the parameters under study. 
For our study with epigallocatechin gallate, 51 participants were random-
ized to either active agent or placebo, which provided more than adequate 
power to detect a 50% difference between active and placebo groups. It was 
felt that this level of activity would be necessary for the agent to be promising 
for future studies and possible development. 
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Surrogate Endpoint Biomarker Analyses 
If possible, in addition to monitoring the clinical status of actinic keratoses 
during the trial of chemopreventive agents, it is desirable to include analyses 
of surrogate endpoint biomarkers for the actinic keratoses and the squamous 
cell carcinomas into which they may evolve. The elucidation of useful surro-
gate endpoint biomarkers is at an early stage for nonmelanoma skin cancer. 
The most likely candidate surrogate endpoint biomarker for actinic keratoses 
and squamous cell carcinoma is p53 (Brash et al. 1991; Einspahr et al. 1997). 
Good candidate surrogate endpoint biomarkers have yet to be identified for 
basal cell carcinoma. 
For our study, we tried to choose a variety of potential surrogate endpoint 
biomarkers, with a goal being the evaluation of the usefulness of these 
biomarkers in chemoprevention studies for actinic keratoses and non-
melanoma skin cancer. The biomarkers selected were: (1) p53, a cell cycle reg-
ulatory protein; (2) Ki-67, a marker of proliferation; (3) CD1A, a Langerhans 
cell marker - Langerhans cells being the main immune surveillance cells of 
the skin; (4) nucleolar number; and (5) various measures of nuclear mor-
phometry, including nuclear size and shape and variability in size and shape. 
We chose these markers because we felt that they have good potential to be 
useful surrogate endpoint biomarkers for actinic keratoses and nonmelanoma 
skin cancer. They represent a wide variety of categories of possible biomark-
ers including cell cycle regulation, cell proliferation, and cellular morphology, 
and because all of these biomarkers can be measured quantitatively in an ob-
jective manner with computer-assisted image analysis. 
Skin biopsies were performed on actinic keratoses, sun-damaged skin, and 
nonsun-damaged skin pretreatment. Also, skin biopsies were performed on 
actinic keratoses and sun-damaged skin in the areas that agent or placebo was 
applied to posttreatment as well. This was done for histopathologic analysis of 
the changes and surrogate endpoint biomarker analysis between the different 
groups represented by the biopsies. 
Results of Our Study Using Topical Epigallocatechin Gallate 
as a Chemopreventive Agent for Actinic Keratoses 
and Nonmelanoma Skin Cancer 
A total of 51 study subjects completed the 12-week study, wherein the agent 
was applied to one forearm with actinic keratoses and placebo ointment to 
the other forearm nightly. Analysis of the clinical monitoring of the target ac-
tinic keratoses at 2-week intervals revealed a slight, progressive decrease in 
grade of severity of the actinic keratoses over the course of the study in both 
the treatment and control groups. There were no statistically significant differ-
ences between the treatment and control groups. This illustrates the necessity 
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of including a control group, without which we might have concluded that the 
agent showed efficacy in the treatment of actinic keratoses. 
Analysis of the surrogate endpoint biomarkers is ongoing; however, analy-
ses have been completed on the majority of the biomarkers. For those com-
pleted, there was no significant difference between the treatment and control 
groups. However, for all biomarkers analyzed to date except CDIA, there are 
statistically significant differences between biomarkers between actinic ker-
atoses and sun-damaged skin and actinic keratoses and nonsun-damaged 
skin. There were nonstatistically significant differences for the surrogate end-
point biomarkers so far analyzed between sun-damaged and nonsun-damaged 
skin. 
Discussion of Results of Topical Epigallocatechin Gallate 
as a Chemopreventive Agent in Nonmelanoma Skin Cancer 
Preliminary analysis of the clinical and surrogate endpoint biomarker data in-
dicates that topical epigallocatechin gallate is not active in the formulation 
used in our study. There are several possible explanations for this. Epigallocat-
echin gallate may simply not be an effective clinical agent for actinic ker-
atoses/nonmelanoma skin cancer. This is certainly a possibility, but one that 
is not easy to reconcile with the impressive animal model data (Mukhtar et al. 
1994; Gensler et al. 1996). Another possibility is that the particular formula-
tion used was not effective. Reasons for this could be that the active com-
pound, epigallocatechin gallate, is not stable in the current formulation, or 
that the compound is stable, but is not being delivered in an effective manner 
to the target site in the skin tissue. The epigallocatechin gallate formulation 
used in this study has undergone repeated stability testing throughout the 
course of the study and shows minimal degradation over the time frame in 
question. As a result, compound instability is not likely to account for the in-
activity of this formulation. Questions about the bioavailability of the specific 
formulation used and possible design of a more effective formulation are areas 
that merit further study. 
Although the current study did not demonstrate agent efficacy, surrogate 
endpoint biomarker analysis is yielding useful data that tentatively support 
the biomarkers chosen (with the exception of CDIA) as having potential in 
differentiating sun-damaged from precancerous and cancerous states. 
Further conclusions await complete analysis of the data. 
Summary 
Nonmelanoma skin cancer constitutes a significant human disease burden 
and new methods of prevention need to be developed. Given the limited suc-
cess of primary behavioral prevention, there is a strong need for chemopre-
ventive agents against nonmelanoma skin cancer. Our study of epigallocate-
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chin gallate for the treatment of actinic keratoses has shown minimal to no 
clinical activity; however, this might be attributable to the particular formula-
tion used. Further data analysis and experiments are underway to better un-
derstand these findings. The surrogate endpoint biomarker analysis, which 
showed differences between actinic keratoses and sun-damaged skin, has 
yielded promising information that will provide insights into biomarkers for 
skin carcinogenesis and potentially help identify surrogate endpoints that 
may prove useful in the design and interpretation of future clinical trials. 
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